Healthcare / Diagnostics & ResearchJakarta
$2780.00
+320.00 (+12.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $251.5B · quality 79.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
66/100
B
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.47T
P/E
11.9x
↓EV/EBITDA
4.4x
↓ROE
8.6%
↑Gross Margin
58.4%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.5%
FCF CAGR
+7.6%
FCF margin
12.3%
FCF / Net income
1.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.28T · net income $206.79B · FCF $279.65B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2281.70B | $2281.70B | $2252.19B | $2222.47B | $2181.64B |
| Net Income | $206.79B | $206.79B | $270.20B | $259.87B | $371.65B |
| EBITDA | $464.65B | $464.65B | $515.61B | $478.95B | $598.17B |
| EPS | 227.25 | 227.25 | 288.21 | 277.20 | 394.87 |
| Gross Margin | 58.4% | 58.4% | 60.0% | 59.4% | 60.8% |
| Operating Margin | 10.0% | 10.0% | 13.2% | 13.8% | 20.5% |
| Net Margin | 9.1% | 9.1% | 12.0% | 11.7% | 17.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 6.44 | 6.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $279.65B | $279.65B | $251.53B | $165.46B | $224.47B |
| Returns | |||||
| ROE | 8.6% | 8.6% | 10.9% | 11.0% | 16.1% |
| Valuation | |||||
| P/E | 11.91 | 11.91 | 9.16 | 19.30 | 13.61 |
| EV/EBITDA | 4.36 | 4.36 | 4.00 | 9.40 | 7.34 |
| P/B | 1.08 | 1.08 | 1.00 | 2.13 | 2.19 |
| Growth & Yield | |||||
| Revenue Growth | 1.3% | 1.3% | 1.3% | 1.9% | — |
| EPS Growth | -21.2% | -21.2% | 4.0% | -29.8% | — |
| Dividend Yield | 6.4% | 6.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
2.8%
EPS terminal req.
$246.68
Spread vs growth
-23.9%
5Y implied EPS CAGR
5.6%
EPS terminal req.
$298.48
Spread vs growth
-26.8%
10Y implied EPS CAGR
7.8%
EPS terminal req.
$480.71
Spread vs growth
-28.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.5%
Start / end P/E
8.7x → 12.5x
EPS bridge
288.21 → 227.25
Residual
-9.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.